With precious little to report out of Sino-U.S. trade talks in London, investors are ready to pounce on almost any sign a ...

So I want to thank Tom Polen, Chairman and Chief Executive Officer of Becton, Dickinson. I appreciate you're making the time. I know you're on the -- you have a lot of different priorities right now.

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Global biopharmaceutical company GlaxoSmithKline (GSK) has pledged $300,000 to UW’s School of Pharmacy for its new Pharmacy Innovation in Immunization Research Collaborative (PIIRC) initiative. On ...

Deal volume fell by 24 per cent to its lowest level since mid-2020, despite predictions of a surge in activity in the wake of ...

GSK PLC GSK shares rallied 1.20% to £15.12 Thursday, on what proved to be an all-around favorable trading session for the ...

The global premenstrual syndrome treatment market is expected to grow at a CAGR of around 5% during the forecast period. This ...

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

GlaxoSmithKline (GSK – Research Report) received a Hold rating and a $41.00 price target from Berenberg Bank analyst Kerry Holford today. Confident Investing Starts Here: Easily ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neuren Pharmaceuticals Limited (NURPF – Research Report), GlaxoSmithKline (GSK – Research Rep ...

GSK PLC closed 11.54% below its 52-week high of £16.79, which the company reached on September 9th.